A. Month 12 follow-up phase

437 enrolled and vaccinated in primary phase
(1xH5N1-AS: 165, 1xH5N1: 61, 2xH5N1-AS: 159, 2xH5N1: 52)

345 enrolled in M12 follow-up phase
(all completed follow-up phase up to M12)

1xH5N1-AS N= 130

ATP persistence cohort (M12) N=112
Excluded: Administration of forbidden vaccine, n=9
Vaccine not administered according to protocol, n=2
Non-compliance with blood sampling schedule, n=7

1xH5N1 N=48

ATP persistence cohort (M12) N=45
Excluded: Administration of forbidden vaccine, n=1
Non-compliance with blood sampling schedule, n=2

2xH5N1-AS N=125

ATP persistence cohort (M12) N=106
Excluded: Administration of forbidden vaccine, n=10
Randomisation failure, n=1
Vaccine not administered according to protocol, n=3
Non-compliance with blood sampling schedule, n=5

2xH5N1 N=42

ATP persistence cohort (M12) N=35
Excluded: Administration of forbidden vaccine, n=2
Vaccine not administered according to protocol, n=4
Non-compliance with blood sampling schedule, n=1

B. Month 24 follow-up phase

320 enrolled in M24 follow-up phase
(all completed follow-up phase up to M24)

1xH5N1-AS N=122

ATP persistence cohort (M24) N=86
Excluded: Administration of forbidden vaccine, n=9
Vaccine not administered according to protocol, n=2
Non-compliance with blood sampling schedule, n=22
Other, n=3

1xH5N1 N=45

ATP persistence cohort (M24) N=37
Excluded: Administration of forbidden vaccine, n=1
Non-compliance with blood sampling schedule, n=7

2xH5N1-AS N=117

ATP persistence cohort (M24) N=81
Excluded: Administration of forbidden vaccine, n=9
Randomisation failure, n=1
Vaccine not administered according to protocol, n=3
Administration of forbidden medication, n=1
Non-compliance with blood sampling schedule, n=21
Other, n=1

2xH5N1 N=36

ATP persistence cohort (M24) N=24
Excluded: Administration of forbidden vaccine, n=1
Vaccine not administered according to protocol, n=4
Non-compliance with blood sampling schedule, n=7